Milestone Pharmaceuticals Inc
NASDAQ:MIST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Milestone Pharmaceuticals Inc
Change in Working Capital
Milestone Pharmaceuticals Inc
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Milestone Pharmaceuticals Inc
NASDAQ:MIST
|
Change in Working Capital
$2.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Change in Working Capital
-$219m
|
CAGR 3-Years
18%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Change in Working Capital
CA$12.9m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
-1%
|
|
|
Cronos Group Inc
TSX:CRON
|
Change in Working Capital
-$34.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Change in Working Capital
$13.6m
|
CAGR 3-Years
59%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Change in Working Capital
CA$1.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Milestone Pharmaceuticals Inc
Glance View
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 29 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Milestone’s lead product candidate is etripamil. The etripamil is a novel, potent and short-acting calcium channel blocker that has been designed rapid-onset nasal spray, which is self-administered by patients. The firm is developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation (AF) and rapid ventricular rate, and other cardiovascular indications.
See Also
What is Milestone Pharmaceuticals Inc's Change in Working Capital?
Change in Working Capital
2.7m
USD
Based on the financial report for Dec 31, 2025, Milestone Pharmaceuticals Inc's Change in Working Capital amounts to 2.7m USD.
What is Milestone Pharmaceuticals Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 1Y
-27%
Over the last year, the Change in Working Capital growth was -27%.
